Belite Bio's drug for genetic eye disease meets main goal in late-stage trial
01/12/2025 11:08
Dec 1 (Reuters) - Belite Bio BLTE.O said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses